A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies	Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, biliary tract disorder, carcinoma, connective tissue neoplasm, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, osteosarcoma, sarcoma, uterine disorder	Recruiting	Phase 1	2026-06-02		NCT07197554

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
SEED Therapeutics, Inc.	1

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana Farber Cancer Institute	Boston	United States	300
Hoag Memorial Hospital	Newport Beach	United States	1
Mass General Brigham Cancer Institute	Boston	United States	3
Memorial Sloan Kettering Cancer Center	New York	United States	1000
The City of Hope National Medical Center	Duarte	United States	1
The University of Texas MD Anderson Cancer Center	Houston	United States	207